Head of IR talks long obesity investment, supply challenges and what makes Novo Nordisk the best place in the world to work
We’ve all read the stories: the success of Novo Nordisk’s diabetes-turned-weight-loss drugs driving a 53 percent share increase over 2023; how the 100-year-old pharmaceutical company grew to be bigger than its next 10 domestic peers; Novo Nordisk’s place as Denmark’s biggest taxpayer, turning what would have been a recession into economic growth; the 10,000-employee-party in a field in Roskilde – the site of one of Europe’s most famous festivals – to celebrate. And the company doesn’t
You need to register to access 3 free deep dive articles per month. To continue reading please register or login below..
- Unlimited deep dives
- Data-driven research around key topics
- Buy-side insights
- Benchmarking reports
From
$1495
Garnet Roach
An award-winning journalist, Garnet Roach joined IR Magazine in October 2012, working on both the editorial and research sides of the publication. Prior to entering the world of investor relations, her freelance career covered a broad range of...
Deputy editor
